Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG4399 in Adult, Healthy, Male Subjects

Next Previous
Trial Profile

A First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG4399 in Adult, Healthy, Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 4399 (Primary)
  • Indications Inflammation
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV; Lakefront Biotherapeutics

Most Recent Events

  • 07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
  • 31 Jan 2022 Status changed from recruiting to completed.
  • 30 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top